ERBB2 and breast cancer: As summarized in Table 4, we focused on the 54 BC with 4.0–5.9 HER2 s/n belonging to our series and we found that 21 (39%) cases presented a normal CEP17 status and 33 (61%) had an increased CEP17 s/n by DDISH.